World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
117
Citations
56380
World Ranking
4180
National Ranking
161

Overview

Hans Gelderblom is affiliated with Leiden University Medical Center in the Netherlands, specializing in medical research with a focus on oncology and related subfields. Their academic output spans a broad spectrum within medicine, with notable concentration in pulmonary and respiratory medicine, oncology, rheumatology, gastroenterology, and surgery.

Their research portfolio prominently features sarcoma diagnosis and treatment alongside gastrointestinal tumor research and treatment. Additional areas of expertise include gastric cancer management and outcomes, musculoskeletal synovial abnormalities and treatments, cancer genomics and diagnostics, cardiac tumors and thrombi, as well as bone tumor diagnosis and treatments.

Gelderblom's work has been published extensively in various scientific journals. Frequent publication venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Cancers
  • ESMO Open

Key recent publications reflect collaboration in clinical guidelines and rigorous clinical trials in oncology, including:

  • Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial, 2020, The Lancet Oncology
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up, 2021, Annals of Oncology

Collaboration is a significant aspect of Gelderblom's research, with frequent coauthors including:

  • Jean-Yves Blay
  • Michiel A. J. van de Sande
  • Robin L. Jones
  • Silvia Stacchiotti
  • Sebastian Bauer

Best Publications

  • Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

    Hans Gelderblom;Jaap Verweij;Kees Nooter;Alex Sparreboom

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Combination Chemotherapy in Advanced Adrenocortical Carcinoma

    Martin Fassnacht;Massimo Terzolo;Bruno Allolio;Eric Baudin

  • The Clinical Approach Towards Chondrosarcoma

    Hans Gelderblom;Pancras C.W. Hogendoorn;Sander D. Dijkstra;Carla S. van Rijswijk

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;J.-Y. Blay

  • Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    Neyssa M Marina;Sigbjørn Smeland;Stefan S Bielack;Mark Bernstein

  • Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Paolo G. Casali;Jean-Yves Blay;Alexia Bertuzzi;Stefan Bielack

  • Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    Sigbjørn Smeland;Stefan S. Bielack;Jeremy Whelan;Mark Bernstein

  • Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

    Jakob K. Anninga;Hans Gelderblom;Marta Fiocco;Judith R. Kroep

  • Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;S. Bielack;N. Abecassis;H.T. Aro

  • Clinical pharmacokinetics of tyrosine kinase inhibitors.

    Nielka P. van Erp;Hans Gelderblom;Henk-Jan Guchelaar

  • Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

    Stefan S. Bielack;Sigbjørn Smeland;Jeremy S. Whelan;Neyssa Marina

  • Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

    Alex Sparreboom;Lia van Zuylen;Eric Brouwer;Walter J. Loos

  • Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    A. Berruti;E. Baudin;H. Gelderblom;H. R. Haak

  • Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;S. Bielack;N. Abecassis;H.T. Aro

Frequent Co-Authors

Henk-Jan Guchelaar
Henk-Jan Guchelaar Leiden University Medical Center
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Silvia Stacchiotti
Silvia Stacchiotti University of Milan
Piotr Rutkowski
Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology
Peter Hohenberger
Peter Hohenberger Heidelberg University
Judith V.M.G. Bovée
Judith V.M.G. Bovée Leiden University Medical Center
Pancras C.W. Hogendoorn
Pancras C.W. Hogendoorn Leiden University Medical Center
Alessandro Gronchi
Alessandro Gronchi University of Milan
Paolo G. Casali
Paolo G. Casali University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine opens doors to a wide range of related online degrees and specialties. Many students interested in healthcare opt for the cheapest online health science degree options to gain foundational knowledge while keeping tuition costs manageable.

For those considering a leadership role, the most affordable mha programs prepare graduates for management positions in healthcare settings. If your goal is advanced clinical practice, there are also cheapest bsn to dnp programs available online, streamlining the journey to a Doctor of Nursing Practice.

Pharmacy is another in-demand branch. Today, it’s possible to earn an online pharmacy degree from accredited institutions, offering more flexibility for aspiring pharmacists. These online programs help students balance career advancement with personal commitments, making them valuable pathways for those pursuing healthcare careers beyond the traditional MD route.

Best Scientists Citing Hans Gelderblom

Trending Scientists

Recently Published Articles